An experimental cancer vaccine in early-stage development at the University of California San Francisco has sparked hope that patients with acute myeloid leukemia (AML), an aggressive cancer of the blood, could one day have a life-saving alternative, especially those prone to relapse or unable to ...

Thea D. Tlsty, PhD, Professor of Pathology and a UCSF leader in cell cycling and signaling, received a $26 million Grand Challenge Grant from Cancer Research UK (CRUK) to lead an international team exploring how chronic inflammation causes cancer. 

Regular use of a common type of medication, such as aspirin and ibuprofen, significantly improves survival for a third or more patients with head and neck cancer, a new study led by UC San Francisco has found.  Non-steroidal anti-inflammatory drugs, or NSAIDs, improved the overall ...

“The Grand Challenge is designed to address really big, intractable questions in cancer. The idea is not to make small, incremental steps, but to make a huge leap forward.” Thea Tlsty, PhD Related news:Q & A with Thea Tlsty, PhD, on Leading International ...

In laboratory experiments, UC San Francisco researchers successfully beat back the growth of aggressive liver cancers using a surprising new approach. Traditionally, targeted cancer therapies aim to disable proteins borne of cancer-driving genes. Instead, the UCSF scientists prevented these proteins, including those that shield tumors ...

Using a divide and conquer strategy, researchers from the University of California San Francisco have provided a road map for the development of a precision medicine approach to osteosarcoma, the most common bone cancer in children and young adults and an aggressive disease for ...